Business
Media
Conferences
Publications
CME/CE
Resources
Subscribe

|Videos|December 20, 2021

How to mitigate adverse events associated with radical cystectomy in women

Author(s)Urology Times staff

“I think discussing it and talking about the different techniques out there [is important],” says Svetlana Avulova, MD.

In this video, Svetlana Avulova, MD, discusses how clinicians can minimize the adverse events associated with radical cystectomy. Avulova is an assistant professor of surgery in urologic oncology at the Albany Medical Center in Albany, New York.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Related Content

Can Aydogdu, MD on using ctDNA to predict nodal metastases at cystectomy

ByCan Aydogdu, MD

July 23rd 2026

KEYNOTE-B15 data on enfortumab vedotin plus pembrolizumab in MIBC published in NEJM

ByHannah Clarke

July 23rd 2026

Improving CIS detection: Diagnostic tools and the urologist–pathologist relationship

ByArpeet Shah, MD,Prithvi Murthy, MD,Kenneth Beck, MD

July 22nd 2026

Prof Declan Murphy on interpreting the PROTEUS trial in localized prostate cancer

ByDeclan Murphy, MB, BCH, BaO, FRACS, FRCS, Urol

July 22nd 2026

Experts discuss the challenge of detecting CIS in bladder cancer

ByArpeet Shah, MD,Prithvi Murthy, MD,Kenneth Beck, MD

July 21st 2026

Latest CME

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Radioligand Therapy 101: The Science Behind the Strategy

Radioligand Therapy 101: The Science Behind the Strategy

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Jeremie Calais, MD, PhD; Scott T. Tagawa, MD, MS, FACP, FASCO

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Ana Kiess, MD, PhD; Erin Grady, MD, CCD, FACNM, FSNMMI; Himanshu Nagar, MD, MS; Scott T. Tagawa, MD, MS, FASCO, FACP

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Trending on Urology Times

FDA grants tentative approval to generic olaparib tablets across previously approved indications

Phase 3 trial launches of CAIX-targeted radiopharmaceutical for ccRCC

FDA grants priority review to talazoparib plus enzalutamide for HRR gene-altered mCSPC

Published data support PSMA-PET–guided selection for 177Lu-rosopatamab tetraxetan in mCRPC

Prof Declan Murphy on interpreting the PROTEUS trial in localized prostate cancer